Relitaz

Relitaz is a purified, standardized allergen preparation derived from honey bee (*Apis mellifera*) venom, developed by Allergopharma GmbH & Co. KG for use in venom immunotherapy (VIT). It is indicated for the treatment of patients with a history of systemic allergic reactions to bee stings and demonstrated IgE-mediated sensitivity. The therapy involves a build-up phase of increasing subcutaneous injections followed by a maintenance phase. Relitaz works by inducing immune tolerance, shifting the immune response from an IgE-mediated Th2 profile toward a Th1 and regulatory T-cell (Treg) dominated profile. This modulation results in the production of allergen-specific blocking IgG4 antibodies and inhibitory cytokines like IL-10, which prevent mast cell and basophil degranulation upon future stings, thereby reducing the risk of anaphylaxis.

Brand names

Relitaz

Other names

Purified honey bee venom (Allergopharma)Honey bee venom extractApis mellifera venom extractBee venom-Allergopharma